- Home
- VIST vs TGTX Comparison
VIST vs TGTX Comparison
Compare VIST & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIST
- TGTX
- Stock Information
- Founded
- VIST 2017
- TGTX 1993
- Country
- VIST Mexico
- TGTX United States
- Employees
- VIST N/A
- TGTX N/A
- Industry
- VIST Oil & Gas Production
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- VIST Energy
- TGTX Health Care
- Exchange
- VIST Nasdaq
- TGTX Nasdaq
- Market Cap
- VIST 5.1B
- TGTX 4.2B
- IPO Year
- VIST 2019
- TGTX 1995
- Fundamental
- Price
- VIST $35.73
- TGTX $32.16
- Analyst Decision
- VIST Strong Buy
- TGTX Strong Buy
- Analyst Count
- VIST 4
- TGTX 4
- Target Price
- VIST $65.75
- TGTX $42.50
- AVG Volume (30 Days)
- VIST 1.3M
- TGTX 2.1M
- Earning Date
- VIST 10-22-2025
- TGTX 11-03-2025
- Dividend Yield
- VIST N/A
- TGTX N/A
- EPS Growth
- VIST 26.19
- TGTX N/A
- EPS
- VIST 5.47
- TGTX 0.36
- Revenue
- VIST $1,982,699,000.00
- TGTX $454,069,000.00
- Revenue This Year
- VIST $38.98
- TGTX $82.58
- Revenue Next Year
- VIST $18.03
- TGTX $44.99
- P/E Ratio
- VIST $6.45
- TGTX $89.15
- Revenue Growth
- VIST 49.52
- TGTX 30.96
- 52 Week Low
- VIST $31.63
- TGTX $21.16
- 52 Week High
- VIST $61.67
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- VIST 35.55
- TGTX 57.84
- Support Level
- VIST $31.63
- TGTX $31.34
- Resistance Level
- VIST $38.73
- TGTX $32.57
- Average True Range (ATR)
- VIST 1.55
- TGTX 1.13
- MACD
- VIST -0.08
- TGTX 0.54
- Stochastic Oscillator
- VIST 48.40
- TGTX 76.20
About VIST Vista Energy S.A.B. de C.V. each representing one series A share with no par value
Vista Energy SAB de CV is an independent oil and gas company. It is focused on shale oil and shale gas exploration at its main assets in Vaca Muerta. The company has operations in Argentina and Mexico. The company operates in a single segment- the exploration and production of Crude oil, Natural gas, and LPG. Geographically, It operates in Argentina and Mexico. it generates the majority of its revenue from Argentina.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.